Quantitative structure-activity relationship study of novel alpha1a-selective adrenoceptor antagonists

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Urology

Background:

• Novel alpha1a-selective adrenoceptor antagonists were developed.
• Two distinct chemical series were synthesized, featuring dihydropyrimidone cores linked to piperidine or piperazine side chains.
• These compounds are investigated for their therapeutic potential in benign prostatic hyperplasia (BPH).

Purpose of the Study:

• To conduct a quantitative structure-activity relationship (QSAR) study on two series of alpha1a-selective adrenoceptor antagonists.
• To identify key structural features and substituent effects influencing binding potency.
• To guide the design of more effective drug candidates for benign prostatic hyperplasia.

Main Methods:

• Synthesis of two series of novel alpha1a-selective adrenoceptor antagonists.
• Quantitative structure-activity relationship (QSAR) analysis was performed.
• Systematic variation of substituents at specific positions (R1, R2, X, meta-, para-positions) to assess their impact on binding affinity.

Main Results:

• For the first series, high field and resonance effects of X- and R1-substituents correlated with increased antagonist potency.
• The R2 substituent (CH3 or C2H5) did not significantly enhance activity, suggesting redundancy at this site.
• In the second series, less polar/bulky substituents at meta- and para-positions, and hydrophobic substituents at the para-position, were found to be advantageous for potency.

Conclusions:

• QSAR analysis elucidated the critical role of specific substituents in modulating the activity of alpha1a-selective adrenoceptor antagonists.
• Structural modifications, particularly concerning electronic and steric properties of substituents, can optimize drug potency.
• These findings provide a rational basis for the future design of improved therapeutics for benign prostatic hyperplasia.